Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A | P11388 | 6/20 | 0.47 |
| ▸ | TOP2B | Q02880 | 6/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.43 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2670607 | 0.85 | CYP3A4 (0.44) | TOP2ATOP2BKDM4EKCNH2ALDH1A1 | |
| SCHEMBL2670640 | 0.81 | TOP2A (0.50) | TOP2ATOP2BKDM4EKCNH2ALDH1A1 | |
| SCHEMBL2670521 | 0.81 | TOP2A (0.49) | TOP2ATOP2BKDM4EKCNH2ALDH1A1 | |
| SCHEMBL2670980 | 0.81 | TOP2A (0.51) | TOP2ATOP2BKDM4EKCNH2ALDH1A1 | |
| SCHEMBL2670396 | 0.79 | KCNH2 (0.52) | TOP2ATOP2BKDM4EKCNH2ALDH1A1 | |
| SCHEMBL7998227 | 0.78 | KDM4E (0.52) | TOP2ATOP2BKDM4EKCNH2ALDH1A1 | |
| SCHEMBL2670762 | 0.76 | KCNH2 (0.46) | TOP2ATOP2BKDM4EKCNH2ALDH1A1 | |
| SCHEMBL8365398 | 0.74 | KDM4E (0.54) | TOP2ATOP2BKDM4EKCNH2ALDH1A1 | |
| SCHEMBL6659404 | 0.73 | TOP2A (0.60) | TOP2ATOP2BKDM4EKCNH2ALDH1A1 | |
| SCHEMBL30891255 | 0.73 | TOP2A (0.60) | TOP2ATOP2BKDM4EKCNH2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130029977-A9 | Fused substituted aminopyrrolidine derivative | DAIICHI SANKYO COMPANY, LIMITED | 2013-01-31 | — | — | US | claimed |
| US-20120108582-A1 | Fused substituted aminopyrrolidine derivative | DAIICHI SANKYO COMPANY, LIMITED | 2012-05-03 | — | — | US | claimed |
| EP-2097400-A2 | FUSED SUBSTITUTED AMINOPYRROLIDINE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2009-09-09 | — | — | EP | claimed |
| WO-2008082009-A2 | FUSED SUBSTITUTED AMINOPYRROLIDINE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2008-07-10 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108582-A1 | Fused substituted aminopyrrolidine derivative | NQO2, QDPR, IL4I1 | TOP2A 89/4885TOP2B 149/4885KDM4E 1244/4885 |
| US-20130029977-A9 | Fused substituted aminopyrrolidine derivative | NQO2, QDPR, IL4I1 | TOP2A 89/4885TOP2B 149/4885KDM4E 1244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.